tissue; tumor cells or tumor DNA isolated from blood, bone marrow, urine, or sputum;
serum or plasma. As much information about the source of the specimen as possible should
be included, for example, whether a tumor sample was obtained at surgery or from a
biopsy procedure such as core needle biopsy or fine needle aspirate. For patients with
advanced disease, it should be clearly stated whether tumor samples assayed came from
the primary tumor site or from a current metastatic lesion and whether the patient had
received any prior cancer-directed therapies (Item 3).
Information about specimen processing and handling might only be ascertainable
indirectly through knowledge of standard operating procedures of the pathology
departments involved. The “Biospecimen Reporting for Improved Study Quality” (BRISQ)
guidelines provide comprehensive recommendations for what information should be reported
regarding specimen characteristics and methods of specimen processing and handling when
publishing research involving the use of biospecimens (7 (link)).
Criteria for acceptability of biospecimens for use in marker studies, such as percent
tumor cellularity, RNA integrity number, percent viable cells, or hemolysis assessment,
should be established before initiating the study. These criteria should be reported,
along with the percentage of specimens that met the criteria and therefore were included
in the study. The numbers of specimens examined at each stage in the study should be
recorded in the suggested flowchart and, particularly, in a study profile (Item 12).